The Clinical Study for Qingfei Huatan Granule to Reduce the Course of Acute Exacerbation of COPD
- Conditions
- Chronic Obstructive Pulmonary Disease,
- Registration Number
- ITMCTR1900002668
- Lead Sponsor
- The First Affiliated Hospital of Anhui University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. A confirmed diagnosis of AECOPD;
2. Syndrome of phlegm-heat obstructing lung;
3. Aged between 40 and 80 years;
4. Voluntary treatment, with the informed consent signed.
1. Pregnant or breast-feeding women;
2. Complicated with cardio-cerebrovascular diseases (malignant arrhythmia, unstable hemodynamics, acute myocardial infarction, NYHA Class III or IV,cerebral apoplexy, cerebral hemorrhage, etc);
3. Complicated with bronchiectasis, bronchial asthma, tuberculosis, bronchiolitis obliterans, diffuse panbronchiolitis, pulmonary embolism pneumothorax and pleural effusion, etc;
4. Complicated with respiratory failure, need endotracheal intubation and ventilator breathing to assist breathing;
5. Complicated with serious liver and renal diseases(Serious liver disease refers to cirrhosis, portal hypertension and varices bleeding,severe kidney disease, including dialysis, kidney transplantation);
6. Combination of tumor or neuromuscular disease affecting the respiratory movement function;
7. Long-term bedridden patients;
8. Congenital or acquired immunodeficiency;
9. Delirious, dementia, and all kinds of psychiatric patients;
10. Patients with oral corticosteroids within 1 mounth before enrollment;
11. Participating in other trials within 1 mounth before enrollment or allergic to the used medicine.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method course of disease;
- Secondary Outcome Measures
Name Time Method TCM syndrome grade;antibiotic use time;lung function;The clinical symptoms and physical signs;Quality of life evaluation;The category and use time of the application of antiasthmatic during the period of COPD exacerbations;Dyspnea;inflammatory indicators;